Professor Ingunn Holen

Clinical Medicine, School of Medicine and Population Health

Professor of Bone Oncology

i.holen@sheffield.ac.uk
+44 114 215 9011

+44 114 271 2475 (Fax)

Room GU24, The Medical School

Full contact details

Professor Ingunn Holen
Clinical Medicine, School of Medicine and Population Health
Room GU24
The Medical School
Beech Hill Road
Sheffield
S10 2RX

Profile

For enquiries please contact - ClinMed-Operational@sheffield.ac.uk

I studied Biology and Biochemistry at the University of Oslo, Norway, and was awarded my PhD for work on the role of autophagy in cancer in 1995. I then joined the University of Sheffield as a post-doctoral research associate working on the mechanism of action of bisphosphonates. Establishing a lab research program in breast cancer bone metastasis, I gained a lectureship in 2001 and was appointed as Professor of Bone Oncology in 2014.

Research interests

The research in my team is focussed on tumour cell dissemination in bone, and how this is influenced by the microenvironment in breast and prostate cancer. In particular we use cutting edge technology to study the early stages of bone metastasis and how single cancer cells may remain dormant or start to proliferate when encountering different environments.

We work to elucidate the molecular mechanisms involved in tumour cell-bone cell interactions, and how these can be targeted by anti-cancer therapies, including CDK4/6 inhibitors. We also investigate the role of the microenvironment in driving progression of bone metastases and collaborate with colleagues in the Dept of Physics and Astronomy to elucidate the biomechanical properties of the bone metastatic niche.

I have several collaborative projects both with other researchers in the medical school, nationally and internationally. I work closely with the clinical staff on translational research projects, transferring the results from our laboratory projects into clinical feasibility studies. Together with colleagues in Leeds, Glasgow and London I have established a national in vivo tissue bank for breast cancer research funded by an “Infrastructure for Impact” grant awarded by the NC3Rs. This initiative is entitled SEARCHBreast and allows researchers to connect with partners who are wiling to share archived material on a collaborative basis thereby not having to carry out in vivo studies. Work in my team has been funded by local, regional and national charities, industry, the EU, MRC, CRUK, BCN, YCR and NC3Rs. In 2018, I and my colleague Dr Penelope Ottwell was awarded the “Julie Philipps PhD Studentship” from the charity Second Hope to support our work on the biology of secondary breast cancer. Our work on the mechanisms of tumour cell dormancy is supported by Weston Park Cancer Charity and Against Breast Cancer.

Ingunn Holden and Penelope Ottwell holding a cheque for £100,000 awarded from Second Hope

Publications

Show: Featured publications All publications

Featured publications

Journal articles

Saleh L, Ottewell PD, Brown JE, Wood SL, Brown NJ, Wilson C, Park C, Ali S & Holen I (2023) The CDK4/6 inhibitor palbociclib inhibits estrogen positive and triple negative breast cancer bone metastasis in vivo. Cancers, 15(8).
Chen X, Hughes R, Mullin N, Hawkins RJ, Holen I, Brown NJ & Hobbs JK (2021) Atomic force microscopy reveals the mechanical properties of breast cancer bone metastases. Nanoscale, 13(43), 18237-18246.
Clezardin P, Coleman R, Puppo M, Ottewell P, Bonnelye E, Paycha F, Confavreux CB & Holen I (2020) Bone metastasis : mechanisms, therapies and biomarkers. Physiological Reviews. View this article in WRRO
Chen X, Hughes R, Mullin N, Hawkins RJ, Holen I, Brown NJ & Hobbs JK (2020) Mechanical Heterogeneity in the Bone Microenvironment as Characterized by Atomic Force Microscopy. Biophysical Journal, 119(3), 502-513.
Ran R, Harrison H, Syamimi Ariffin N, Ayub R, Pegg HJ, Deng W, Mastro A, Ottewell PD, Mason SM, Blyth K , Holen I et al (2020) A role for CBFβ in maintaining the metastatic phenotype of breast cancer cells. Oncogene, 39, 2624-2637. View this article in WRRO
Lefley D, Howard F, Arshad F, Bradbury S, Brown H, Tulotta C, Eyre R, Alférez D, Wilkinson JM, Holen I , Clarke RB et al (2019) Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts. Breast Cancer Research, 21(1). View this article in WRRO
Hughes R, Chen X, Hunter KD, Hobbs JK, Holen I & Brown NJ (2019) Bone marrow osteoprogenitors are depleted whereas osteoblasts are expanded independent of the osteogenic vasculature in response to zoledronic acid. The FASEB Journal, 33(11), 12768-12779. View this article in WRRO
Allocca G, Hughes R, Wang N, Brown HK, Ottewell PD, Brown NJ & Holen I (2019) The bone metastasis niche in breast cancer–potential overlap with the haematopoietic stem cell niche in vivo. Journal of Bone Oncology, 17. View this article in WRRO
Quayle LA, Ottewell PD & Holen I (2018) Chemotherapy resistance and stemness in mitotically quiescent human breast cancer cells identified by fluorescent dye retention. Clinical and Experimental Metastasis. View this article in WRRO
Brown HK, Allocca G, Ottewell PD, Wang N, Brown NJ, Croucher PI, Eaton CL & Holen I (2018) Parathyroid Hormone (PTH) Increases Skeletal Tumour Growth and Alters Tumour Distribution in an In Vivo Model of Breast Cancer.. International Journal of Molecular Sciences, 19(10). View this article in WRRO
Ubellacker JM, Baryawno N, Severe N, DeCristo MJ, Sceneay J, Hutchinson JN, Haider M-T, Rhee CS, Qin Y, Gregory WM , Garrido-Castro AC et al (2018) Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer. American Journal of Cancer, 78(18), 5300-5314. View this article in WRRO
Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Wood SL, Ottewell PD, Marshall H, Banks RE , Selby PJ et al (2016) CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment. Journal of the National Cancer Institute, 108(4). View this article in WRRO
Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body J-J, Markopoulos C, Santini D , Diel I et al (2016) Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Annals of Oncology, 27(3), 379-390.

Conference proceedings papers

Ubellacker JM, Baryawno N, Severe N, DeCristo MJ, Sceneay J, Haider M-T, Rhee CS, Qin Y, Holen I, Gregory WM , Brown JE et al (2018) Abstract B13: Plasma G-CSF levels are predictive of lack of response to zoledronic acid treatment in reducing breast cancer recurrence. Early Clinical Opportunities
Lefley D, Nutter F, Brown H, Tulotta C, Eyre R, Clarke R, Alferez D, Wilkinson M, Holen I & Ottewell P (2017) Human specific models for studying ER plus ve and ER- ve breast cancer bone metastasis. CLINICAL & EXPERIMENTAL METASTASIS, Vol. 34(8) (pp 516-516) View this article in WRRO

All publications

Journal articles

Holen I & Edwards C (2024) Editors' introduction: The microenvironment in bone metastasis – New dimensions. Journal of Bone Oncology, 100633-100633.
Saleh L, Ottewell PD, Brown JE, Wood SL, Brown NJ, Wilson C, Park C, Ali S & Holen I (2023) The CDK4/6 inhibitor palbociclib inhibits estrogen positive and triple negative breast cancer bone metastasis in vivo. Cancers, 15(8).
Porter I, Theodoulou E, Holen I, Harper-Wynne C, Baron-Hay S, Wilson C & Brown J (2021) Adoption of adjuvant bisphosphonates for early breast cancer into standard clinical practice: Challenges and lessons learnt from comparison of the UK and Australian experience. Journal of Bone Oncology, 31, 100402-100402.
Saleh L, Wilson C & Holen I (2021) CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer.. MedComm (2020), 2(4), 514-530.
Chen X, Hughes R, Mullin N, Hawkins RJ, Holen I, Brown NJ & Hobbs JK (2021) Atomic force microscopy reveals the mechanical properties of breast cancer bone metastases. Nanoscale, 13(43), 18237-18246.
Clezardin P, Coleman R, Puppo M, Ottewell P, Bonnelye E, Paycha F, Confavreux CB & Holen I (2020) Bone metastasis : mechanisms, therapies and biomarkers. Physiological Reviews. View this article in WRRO
Holen I & Quayle L (2020) Stem cell niches in bone and their roles in cancer metastasis.
Chen X, Hughes R, Mullin N, Hawkins RJ, Holen I, Brown NJ & Hobbs JK (2020) Mechanical Heterogeneity in the Bone Microenvironment as Characterized by Atomic Force Microscopy. Biophysical Journal, 119(3), 502-513.
Ran R, Harrison H, Syamimi Ariffin N, Ayub R, Pegg HJ, Deng W, Mastro A, Ottewell PD, Mason SM, Blyth K , Holen I et al (2020) A role for CBFβ in maintaining the metastatic phenotype of breast cancer cells. Oncogene, 39, 2624-2637. View this article in WRRO
Baron-Hay S, Theodoulou E, Porter I, Wilson C, Holen I, Harper-Wynne C & Brown J (2020) Abstract P2-18-08: Inclusion of adjuvant bone-modifying agents for early breast cancer into standard clinical practice: Challenges and lessons learnt from an international collaboration. Abstracts: 2019 San Antonio Breast Cancer Symposium.
Saleh L, Wilson C & Holen I (2020) CDK4/6 inhibitors in breast cancer – from in vitro models to clinical trials. Acta Oncologica, 59(2), 219-232.
Lefley D, Howard F, Arshad F, Bradbury S, Brown H, Tulotta C, Eyre R, Alférez D, Wilkinson JM, Holen I , Clarke RB et al (2019) Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts. Breast Cancer Research, 21(1). View this article in WRRO
Hughes R, Chen X, Hunter KD, Hobbs JK, Holen I & Brown NJ (2019) Bone marrow osteoprogenitors are depleted whereas osteoblasts are expanded independent of the osteogenic vasculature in response to zoledronic acid. The FASEB Journal, 33(11), 12768-12779. View this article in WRRO
Allocca G, Hughes R, Wang N, Brown HK, Ottewell PD, Brown NJ & Holen I (2019) The bone metastasis niche in breast cancer–potential overlap with the haematopoietic stem cell niche in vivo. Journal of Bone Oncology, 17. View this article in WRRO
Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter-Howard F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury S et al (2019) Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment. Clinical Cancer Research, 25(9), 2769-2782. View this article in WRRO
Quayle LA, Ottewell PD & Holen I (2018) Chemotherapy resistance and stemness in mitotically quiescent human breast cancer cells identified by fluorescent dye retention. Clinical and Experimental Metastasis. View this article in WRRO
Brown HK, Allocca G, Ottewell PD, Wang N, Brown NJ, Croucher PI, Eaton CL & Holen I (2018) Parathyroid Hormone (PTH) Increases Skeletal Tumour Growth and Alters Tumour Distribution in an In Vivo Model of Breast Cancer.. International Journal of Molecular Sciences, 19(10). View this article in WRRO
Ubellacker JM, Baryawno N, Severe N, DeCristo MJ, Sceneay J, Hutchinson JN, Haider M-T, Rhee CS, Qin Y, Gregory WM , Garrido-Castro AC et al (2018) Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer. American Journal of Cancer, 78(18), 5300-5314. View this article in WRRO
Mittal S, Brown NJ & Holen I (2018) The breast tumor microenvironment: role in cancer development, progression and response to therapy. Expert Review of Molecular Diagnostics, 18(3), 227-243. View this article in WRRO
Holen I, Speirs V, Morrissey B & Blyth K (2017) In vivo models in breast cancer research: progress, challenges and future directions. Disease Models and Mechanisms, 10, 359-371.
Ubellacker JM, Haider MT, DeCristo MJ, Allocca G, Brown NJ, Silver DP, Holen I & McAllister SS (2017) Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells. Breast Cancer Research, 19(1). View this article in WRRO
Morrissey B, Blyth K, Carter P, Chelala C, Jones L, Holen I & Speirs V (2017) The Sharing Experimental Animal Resources, Coordinating Holdings (SEARCH) Framework: Encouraging Reduction, Replacement, and Refinement in Animal Research.. PLoS Biol, 15(1), e2000719-e2000719. View this article in WRRO
Morrissey B, Holen I, Chelala C, Carter P, Jones L, Blyth K & Speirs V (2016) Introducing SEARCHBreast: a virtual resource to facilitate sharing of surplus animal material developed for breast cancer research. npj Breast Cancer, 2(1). View this article in WRRO
Wilson C, Brown H & Holen I (2016) The endocrine influence on the bone microenvironment in early breast cancer.. Endocrine-Related Cancer. View this article in WRRO
Holen I, Lefley DV, Francis SE, Rennicks S, Bradbury S, Coleman RE & Ottewell P (2016) IL-1 drives breast cancer growth and bone metastasis in vivo.. Oncotarget, 7, 75571-75584. View this article in WRRO
Holen I (2016) The bone microenvironment - Multiple players involved in cancer progression.. J Bone Oncol, 5(3), 87-89. View this article in WRRO
Carter P, Blyth K, Holen I, Jones L, Morrissey B, Speirs V & Chelala C (2016) The SEARCHBreast portal: A virtual bioresource to facilitate the sharing of surplus animal materials derived from breast cancer studies. Open Journal of Bioresources, 3. View this article in WRRO
Speirs V, Morrisey B, Holen I, Blyth K, Carter P, Chelala C & Jones L (2016) SEARCHBreast: An online resource designed to increase the efficiency of using materials derived from breast cancer studies in animals.. Breast Cancer Research and Treatment, 156(3), 447-452. View this article in WRRO
Morrissey B, Blyth K, Carter P, Chelala C, Jones L, Holen I & Speirs V (2016) SEARCHBreast: A new online resource to make surplus material from in vivo models of breast cancer visible and accessible to researchers. Breast Cancer Research, 18(1). View this article in WRRO
Holen I (2016) The bone microenvironment – Multiple players involved in cancer progression. Journal of Bone Oncology. View this article in WRRO
De Felice M, Lambert D, Holen I, Escott KJ & Andrew D (2016) Effects of Src-kinase inhibition in cancer-induced bone pain. Molecular Pain, 12, 1-14. View this article in WRRO
Blyth K, Carter P, Morrissey B, Chelala C, Jones L, Holen I & Speirs V (2016) SEARCHBreast: a new resource to locate and share surplus archival material from breast cancer animal models to help address the 3Rs. Breast Cancer Research and Treatment, 156(3), 447-452. View this article in WRRO
Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Wood SL, Ottewell PD, Marshall H, Banks RE , Selby PJ et al (2016) CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment. Journal of the National Cancer Institute, 108(4). View this article in WRRO
Holen I, Walker M, Nutter F, Fowles A, Evans CA, Eaton CL & Ottewell PD (2016) Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo. Clinical & Experimental Metastasis, 33(3), 211-224. View this article in WRRO
Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body J-J, Markopoulos C, Santini D , Diel I et al (2016) Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Annals of Oncology, 27(3), 379-390.
Morrissey B, Blyth K, Carter P, Chelala C, Holen I, Jones L & Speirs V (2015) SEARCHBreast Workshop Proceedings: 3D Modelling of Breast Cancer. Alternatives to Laboratory Animals, 43(6), 367-375.
Wang N, Reeves KJ, Brown HK, Fowles ACM, Docherty FE, Ottewell PD, Croucher PI, Holen I & Eaton CL (2015) The frequency of osteolytic bone metastasis is determined by conditions of the soil, not the number of seeds; evidence from in vivo models of breast and prostate cancer. Journal of Experimental and Clinical Cancer Research, 34(1), 124-124. View this article in WRRO
Haider M-T, Hunter KD, Robinson SP, Graham TJ, Corey E, Dear TN, Hughes R, Brown NJ & Holen I (2015) Rapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivo. Bone, 81, 581-592. View this article in WRRO
Ottewell PD, Wang N, Brown HK, Fowles CA, Croucher PI, Eaton CL & Holen I (2015) OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone. International Journal of Cancer, 137(4), 968-977. View this article in WRRO
Holen I, Nutter F, Wilkinson JM, Evans CA, Avgoustou P & Ottewell PD (2015) Human breast cancer bone metastasis in vitro and in vivo: a novel 3D model system for studies of tumour cell-bone cell interactions. Clinical & Experimental Metastasis, 32(7), 689-702. View this article in WRRO
Wang N, Docherty F, Brown HK, Reeves K, Fowles A, Lawson M, Ottewell PD, Holen I, Croucher PI & Eaton CL (2015) Mitotic quiescence, but not unique “stemness,” marks the phenotype of bone metastasis-initiating cells in prostate cancer. The FASEB Journal, 29(8), 3141-3150. View this article in WRRO
Talari ACS, Evans CA, Holen I, Coleman RE & Rehman IU (2015) Raman spectroscopic analysis differentiates between breast cancer cell lines. Journal of Raman Spectroscopy, 46(5), 421-427. View this article in WRRO
Quayle L, Ottewell P & Holen I (2015) Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer. Current Cancer Drug Targets, 15(6), 469-480.
Wilson C, Ottewell P, Coleman RE & Holen I (2015) The differential anti-tumour effects of zoledronic acid in breast cancer – evidence for a role of the activin signaling pathway. BMC Cancer, 15(1). View this article in WRRO
Ottewell PD, O’Donnell L & Holen I (2015) Molecular alterations that drive breast cancer metastasis to bone. BoneKEy Reports, 4. View this article in WRRO
Wang N, Docherty FE, Brown HK, Reeves KJ, Fowles ACM, Ottewell PD, Dear TN, Holen I, Croucher PI & Eaton CL (2014) Prostate cancer cells preferentially home to osteoblast-rich areas in the early stages of bone metastasis: evidence from in vivo models.. J Bone Miner Res, 29(12), 2688-2696. View this article in WRRO
Ottewell PD, Wang N, Meek J, Fowles CA, Croucher PI, Eaton CL & Holen I (2014) Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocrine Related Cancer, 21(5), 769-781.
Haider M-T, Holen I, Dear TN, Hunter K & Brown HK (2014) Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.. Bone, 66, 240-250.
Ottewell PD, Wang N, Brown HK, Reeves KJ, Fowles CA, Croucher PI, Eaton CL & Holen I (2014) Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.. Clinical Cancer Research, 20(11), 2922-2932. View this article in WRRO
David M, Machuca-Gayet I, Kikuta J, Ottewell P, Mima F, Leblanc R, Bonnelye E, Ribeiro J, Holen I, Vales RL , Jurdic P et al (2014) Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity. Journal of Biological Chemistry, 289(10), 6551-6564.
Nutter F, Holen I, Brown HK, Cross SS, Evans CA, Walker M, Coleman RE, Westbrook JA, Selby PJ, Brown JE & Ottewell PD (2014) Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line.. Endocr Relat Cancer, 21(2), 327-341.
Dougall WC, Holen I & González Suárez E (2014) Targeting RANKL in metastasis.. Bonekey Rep, 3, 519. View this article in WRRO
Mashima I & Nakazawa F (2013) A review on the characterization of a novel oral Veillonella species, V. tobetsuensis, and its role in oral biofilm formation. Journal of Oral Biosciences, 55(4), 184-190.
Rogers TL, Wind N, Hughes R, Nutter F, Brown HK, Vasiliadou I, Ottewell PD & Holen I (2013) Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models.. Cell Oncol (Dordr), 36(6), 505-514.
Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE , Bundred NJ et al (2013) Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research(5), R92. View this article in WRRO
Coleman RE, Gregory W, Marshall H, Wilson C & Holen I (2013) The metastatic microenvironment of breast cancer: Clinical implications. The Breast, 22(Sup 2), S50-S56.
Winter MC, Wilson C, Syddall SP, Cross SS, Evans A, Ingram CE, Jolley IJ, Hatton MQ, Freeman JV, Mori S , Holen I et al (2013) Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer--a randomized biomarker pilot study.. Clin Cancer Res, 19(10), 2755-2765.
Vasiliadou I & Holen I (2013) The role of macrophages in bone metastasis. Journal of Bone Oncology, 2(4), 158-166.
Wilson C, Winter MC, Holen I, Freeman JV, Evans AC & Coleman RE (2012) Abstract P2-02-04: The interaction between menopausal status and zoledronic acid can differentially affect serum levels of the TGFβ superfamily.. Poster Session Abstracts.
Holen I, Wang N, Reeves KJ, Fowles AM, Croucher PI, Eaton CL & Ottewell PD (2012) Abstract PD07-08: Zoledronic acid specifically inhibits development of bone metastases in the post-menopausal setting – evidence from an in vivo breast cancer model. Poster Discussion Abstracts.
Brown HK, Ottewell PD, Evans CA, Coleman RE & Holen I (2012) A single administration of combination therapy inhibits breast tumour progress bone and modifies both osteoblasts and osteoclasts. Journal of Bone Oncology, 1(2), 47-56. View this article in WRRO
Holen I, Whitworth J, Nutter F, Evans A, Brown HK, Lefley DV, Barbaric I, Jones M & Ottewell PD (2012) Loss of plakoglobin promotes decreased cell-cell contact, increased invasion, and breast cancer cell dissemination in vivo.. Breast Cancer Res, 14(3), R86. View this article in WRRO
Brown HK, Ottewell PD, Evans CA & Holen I (2012) Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo.. Clin Exp Metastasis, 29(8), 927-938.
Wilson C, Holen I & Coleman RE (2012) Seed, soil and secreted hormones: potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates.. Cancer Treat Rev, 38(7), 877-889.
Michailidou M & Holen I (2012) Combinations of bisphosphonates and classical anticancer drugs: a preclinical perspective.. Recent Results Cancer Res, 192, 145-169.
Ottewell PD, Whitworth J, Cross SS, Nutter FH & Holen I (2011) P2-01-20: Reduced Plakoglobin Expression Increases the Metastatic Potential of Breast Cancer Cells.. Poster Session Abstracts.
Ottewell PD, Brown HK, Jones M, Rogers TL, Cross SS, Brown NJ, Coleman RE & Holen I (2011) Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice. Breast Cancer Research and Treatment, 1-14.
Wind NS & Holen I (2011) Multidrug resistance in breast cancer: from in vitro models to clinical studies.. Int J Breast Cancer, 2011, 967419. View this article in WRRO
Rogers TL & Holen I (2011) Tumour macrophages as potential targets of bisphosphonates. Journal of Translational Medicine, 9(1).
Brown HK, Ottewell PD, Coleman RE & Holen I (2011) The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells.. J Cell Mol Med, 15(3), 501-513. View this article in WRRO
Holen I & Coleman RE (2010) Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.. Breast Cancer Res, 12(6), 214. View this article in WRRO
Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, Holen I, Mönkkönen H, Boccadoro M, Forni G , Musiani P et al (2010) Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway.. J Cell Mol Med, 14(12), 2803-2815. View this article in WRRO
Syddall SP, Ottewell PD & Holen I (2010) Combined therapies of bone disease with bisphosphonates.. Curr Pharm Des, 16(27), 2988-2997.
Kobayashi-Sakamoto M, Isogai E & Holen I (2010) Osteoprotegerin induces cytoskeletal reorganization and activates FAK, Src, and ERK signaling in endothelial cells. EUR J HAEMATOL, 85(1), 26-35.
Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clézardin P, Croucher PI, Gralow JR, Hadji P , Holen I et al (2010) Metastasis and bone loss: advancing treatment and prevention.. Cancer Treat Rev, 36(8), 615-620. View this article in WRRO
Michailidou M, Brown HK, Lefley DV, Evans A, Cross SS, Coleman RE, Brown NJ & Holen I (2010) Microvascular endothelial cell responses in vitro and in vivo: modulation by zoledronic acid and paclitaxel?. J Vasc Res, 47(6), 481-493.
Clyburn RD, Reid P, Evans CA, Lefley DV & Holen I (2010) Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy.. Cancer Chemother Pharmacol, 65(5), 969-978.
Neville-Webbe HL, Coleman RE & Holen I (2010) Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction.. Br J Cancer, 102(6), 1010-1017. View this article in WRRO
Holen I & Coleman RE (2010) Bisphosphonates as treatment of bone metastases.. Curr Pharm Des, 16(11), 1262-1271.
Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE & Holen I (2010) Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model.. Int J Cancer, 126(2), 522-532.
Cawthorn TR, Amir E, Broom R, Freedman O, Gianfelice D, Barth D, Wang D, Holen I, Done SJ & Clemons M (2009) Mechanisms and pathways of bone metastasis: challenges and pitfalls of performing molecular research on patient samples. CLIN EXP METASTAS, 26(8), 935-943.
Brown HK & Holen I (2009) Anti-tumour effects of bisphosphonates--what have we learned from in vivo models?. Curr Cancer Drug Targets, 9(7), 807-823.
Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE & Holen I (2009) Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.. Mol Cancer Ther, 8(10), 2821-2832.
Xue X, Teare MD, Holen I, Zhu YM & Woll PJ (2009) Optimizing the yield and utility of circulating cell-free DNA from plasma and serum.. Clin Chim Acta, 404(2), 100-104. View this article in WRRO
Bundred NJ, Landberg G, Coleman RE, Morris J, Winter MC, Holen I, Cramer A, Renshaw L, Grassby S & Dixon JM (2009) Short-term biological effects of zoledronic acid combined with letrozole in postmenopausal women with estrogen receptor-positive invasive breast cancer. Journal of Clinical Oncology, 27(15_suppl), e11625-e11625.
Ottewell PD, Lefley DV, Coleman RE & Holen I (2009) Evaluation of the molecular mechanisms for the sequence-dependent, synergistic anti-tumour effects of doxorubicin and zoledronic acid in breast cancer.. Poster Session Abstracts.
Reid PE, Brown NJ & Holen I (2009) Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact.. Mol Cancer, 8, 49. View this article in WRRO
Reid P & Holen I (2009) Pathophysiological roles of osteoprotegerin (OPG).. Eur J Cell Biol, 88(1), 1-17.
Cross NA, Fowles A, Reeves K, Jokonya N, Linton K, Holen I, Hamdy FC & Eaton CL (2008) Imaging the effects of castration on bone turnover and hormone-independent prostate cancer colonization of bone.. Prostate, 68(15), 1707-1714.
Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE & Holen I (2008) Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.. J Natl Cancer Inst, 100(16), 1167-1178.
Winter MC, Holen I & Coleman RE (2008) Exploring the anti-tumour activity of bisphosphonates in early breast cancer.. Cancer Treat Rev, 34(5), 453-475.
Ottewell PD, Deux B, Mönkkönen H, Cross S, Coleman RE, Clezardin P & Holen I (2008) Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.. Clin Cancer Res, 14(14), 4658-4666.
Cross NA, Waterman EA, Jokonya N, Fowles A, Buckle CH, Phillips J, Holen I, Hamdy FC & Eaton CL (2008) Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells.. J Cell Biochem, 104(4), 1452-1464.
Mönkkönen H, Kuokkanen J, Holen I, Evans A, Lefley DV, Jauhiainen M, Auriola S & Mönkkönen J (2008) Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth. Anti-Cancer Drugs, 19(4), 391-399.
Thompson A, Brennan K, Cox A, Gee J, Harcourt D, Harris A, Harvie M, Holen I, Howell A, Nicholson R , Steel M et al (2008) Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. BREAST CANCER RES, 10(2). View this article in WRRO
Holen I (2008) PL9.3. Is the antitumour efficacy of bisphosphonates clinically relevant?. Cancer Treatment Reviews, 34, 49-49.
Woodward JKL, Holen I, Coleman RE & Buttle DJ (2007) The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer.. Bone, 41(6), 912-927.
Waterman EA, Cross NA, Lippitt JM, Cross SS, Rehman I, Holen I, Hamdy FC & Eaton CL (2007) The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.. Int J Cancer, 121(9), 1958-1966.
Mönkkönen H, Ottewell PD, Kuokkanen J, Mönkkönen J, Auriola S & Holen I (2007) Zoledronic acid-induced IPP/ApppI production in vivo.. Life Sci, 81(13), 1066-1070.
Xue X, Teare MD, Holen I, Zhu YM & Woll PJ (2007) P2-062: Optimizing the yield of circulating DNA from plasma and serum. Journal of Thoracic Oncology, 2(8), S514-S515.
Cross SS, Harrison RF, Balasubramanian SP, Lippitt JM, Evans CA, Reed MWR & Holen I (2006) Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.. J Clin Pathol, 59(7), 716-720.
Santini D, Caraglia M, Vincenzi B, Holen I, Scarpa S, Budillon A & Tonini G (2006) Mechanisms of Disease: preclinical reports of antineoplastic synergistic action of bisphosphonates. NAT CLIN PRACT ONCOL, 3(6), 325-338.
Santini D, Vincenzi B, Hannon RA, Brown JE, Dicuonzo G, Angeletti S, La Cesa A, Coleman RE, Tonini G, Budillon A , Caraglia M et al (2006) Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. ONCOL REP, 15(5), 1351-1357.
Cross SS, Yang Z, Brown NJ, Balasubramanian SP, Evans CA, Woodward JK, Neville-Webbe HL, Lippitt JM, Reed MWR, Coleman RE & Holen I (2006) Osteoprotegerin (OPG)--a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis?. Int J Cancer, 118(8), 1901-1908.
Cross N, Waterman E, Jokonya N, Holen I, Hamdy F & Eaton C (2006) OSTEOPROTEGERIN DERIVED FROM TUMOUR CELLS OR FROM BONE MARROW CELL TYPES DIFFERS IN ITS ACTIVITY AS A SURVIVAL FACTOR FOR PROSTATE CANCER. European Urology Supplements, 5(2), 124-124.
Holen I & Shipman CM (2006) Role of osteoprotegerin (OPG) in cancer.. Clin Sci (Lond), 110(3), 279-291.
Ottewell PD, Coleman RE & Holen I (2006) From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies.. Breast Cancer Res Treat, 96(2), 101-113.
Vincenzi B, Santini D, Holen I & Tonini G (2006) Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. Haematologica Reports, 2(3), 50-51.
Michailidou M, Neville-Webbe HL, Woodward JK, Lefley DV, Brown NJ, Coleman RE & Holen I (2006) The effects of combined treatment using paclitaxel and zoledronic acid on tumour cells and endothelial cells in vitro. Haematologica Reports, 2(3), 48-49.
Neville-Webbe HL, Evans CA, Coleman RE & Holen I (2006) Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro.. Tumour Biol, 27(2), 92-103.
Van Poznak C, Cross SS, Saggese M, Hudis C, Panageas KS, Norton L, Coleman RE & Holen I (2006) Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.. J Clin Pathol, 59(1), 56-63.
Santini D, Vincenzi B, Hannon RA, Brown J, La Cesa A, Holen I & Tonini G (2005) Correlations of vessel endothelial growth factor (VEGF) and B crosslinked type I collagen C-telopeptide (bCTX) after a single zoledronic acid infusion in patients with tumour-induced bone disease. ANN ONCOL, 16, 32-32.
Woodward JKL, Neville-Webbe HL, Coleman RE & Holen I (2005) Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro.. Anticancer Drugs, 16(8), 845-854.
Holen I, Cross SS, Neville-Webbe HL, Cross NA, Balasubramanian SP, Croucher PI, Evans CA, Lippitt JM, Coleman RE & Eaton CL (2005) Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival?. Breast Cancer Res Treat, 92(3), 207-215.
Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE & Holen I (2005) Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells.. Int J Cancer, 113(3), 364-371.
Woodward JKL, Coleman RE & Holen I (2005) Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion.. Anticancer Drugs, 16(1), 11-19.
Nyambo R, Cross N, Lippitt J, Holen I, Bryden G, Hamdy FC & Eaton CL (2004) Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.. J Bone Miner Res, 19(10), 1712-1721.
Gilbey AM, Burnett D, Coleman RE & Holen I (2004) The detection of circulating breast cancer cells in blood. J CLIN PATHOL, 57(9), 903-911.
Neville-Webbe HL, Cross NA, Eaton CL, Nyambo R, Evans CA, Coleman RE & Holen I (2004) Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis.. Breast Cancer Res Treat, 86(3), 269-279.
Eaton CL, Wells JM, Holen I, Croucher PI & Hamdy FC (2004) Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.. Prostate, 59(3), 304-310.
Chandrasekharan S, Hamdy FC, Holen I, Cross N & Buttle DJ (2003) Expression pattern of the ADAMTS proteinases in human prostate cancer cell lines. European Urology Supplements, 2(1), 60-60.
Neville-Webbe HL, Holen I & Coleman RE (2002) The anti-tumour activity of bisphosphonates.. Cancer Treat Rev, 28(6), 305-319.
Holen I, Croucher PI, Hamdy FC & Eaton CL (2002) Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.. Cancer Res, 62(6), 1619-1623.
Holen I, Eaton C, Hamdy F & Croucher P (2002) Production of osteoprotegerin by prostate cancer cells suppresses trial induced apoptosis. European Urology Supplements, 1(1), 54-54.
Wells J, Holen I, Croucher P, Hamdy F & Eaton C (2002) Serum osteoprotegerin levels are increased in hormone resistant prostate cancer patients. European Urology Supplements, 1(1), 159-159.
Holen I, Drury NL, Hargreaves PG & Croucher PI (2001) Evidence of a role for a non-matrix-type metalloproteinase activity in the shedding of syndecan-1 from human myeloma cells.. Br J Haematol, 114(2), 414-421.
Vankemmelbeke MN, Holen I, Wilson AG, Ilic MZ, Handley CJ, Kelner GS, Clark M, Liu C, Maki RA, Burnett D & Buttle DJ (2001) Expression and activity of ADAMTS-5 in synovium.. Eur J Biochem, 268(5), 1259-1268.
Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A, Brabbs AC, van Beek EJ, Holen I, Skerry TM , Dunstan CR et al (2001) Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.. Blood, 98(13), 3534-3540.
Shipman CM, Holen I, Lippitt JM, Vandenberghe E & Croucher PI (2000) Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.. BLOOD, 96(11), 360A-360A.
Ilic MZ, Vankemmelbeke MN, Holen I, Buttle DJ, Clem Robinson H & Handley CJ (2000) Bovine joint capsule and fibroblasts derived from joint capsule express aggrecanase activity.. Matrix Biol, 19(3), 257-265.
Holen I, Dury NL, Hargreaves PG & Croucher PI (2000) Human myeloma cells shed syndecan-1 in vitro: Evidence for mediation by a non-matrix metallproteinase.. J BONE MINER RES, 15(6), 1222-1222.
Shipman CM, Holen I, Lippitt JM, Edwards T & Croucher PI (2000) Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.. J BONE MINER RES, 15(6), 1217-1217.
Luckman SP, Hughes DE, Chilton KM, Coxon FP, Holen I, Russell RGG, Ebetino FH & Rogers MJ (1997) Bisphosphonates act by inhibiting protein prenylation.. J BONE MINER RES, 12, T372-T372.
Seglen PO, Berg TO, Blankson H, Fengsrud M, Holen I & Strømhaug PE (1996) Structural Aspects of Autophagy, 103-111.
Holen I, Gordon PB, Stromhaug PE & Seglen PO (1996) Role of cAMP in the Regulation of Hepatocytic Autophagy. European Journal of Biochemistry, 236(1), 163-170.
Blankson H, Holen I & Seglen PO (1995) Disruption of the Cytokeratin Cytoskeleton and Inhibition of Hepatocytic Autophagy by Okadaic Acid. Experimental Cell Research, 218(2), 522-530.
Holen I, Str PE, Gordon PB, Fengsrud M, Berg TO & Seglen PO (1995) Inhibition of Autophagy and Multiple Steps in Asialoglycoprotein Endocytosis by Inhibitors of Tyrosine Protein Kinases (Tyrphostins). Journal of Biological Chemistry, 270(21), 12823-12831.
Holen I, Gordon PB, Strømhaug PE, Berg TO, Fengsrud M, Brech A, Roos N, Berg T & Seglen PO (1995) Inhibition of asialoglycoprotein endocytosis and degradation in rat hepatocytes by protein phosphatase inhibitors. Biochemical Journal, 311(1), 317-326.
Gordon PB, Holen I & Seglen PO (1995) Protection by Naringin and Some Other Flavonoids of Hepatocytic Autophagy and Endocytosis against Inhibition by Okadaic Acid. Journal of Biological Chemistry, 270(11), 5830-5838.
Gordon PB, Holen I, Fosse M, Røtnes JS & Seglen PO (1993) Dependence of hepatocytic autophagy on intracellularly sequestered calcium.. Journal of Biological Chemistry, 268(35), 26107-26112.
HOLEN I, GORDON PB & SEGLEN PO (1993) Inhibition of hepatocytic autophagy by okadaic acid and other protein phosphatase inhibitors. European Journal of Biochemistry, 215(1), 113-122.
Holen I, Gordon PB & Seglen PO (1992) Protein kinase-dependent effects of okadaic acid on hepatocytic autophagy and cytoskeletal integrity. Biochemical Journal, 284(3), 633-636.
Seglen PO, Gordon PB, Holen I & Hoyvik H (1991) Hepatocytic autophagy. Biomedica Biochimica Acta, 50(4-6), 373-381.
Seglen PO, Gordon PB & Holen I (1990) Non-selective autophagy.. Seminars in cell biology, 1(6), 441-448.
Holen I, Mikalsen S & Sanner T (1990) Effects of dinitrotoluenes on morphological cell transformation and intercellular communication in Syrian hamster embryo cells. Journal of Toxicology and Environmental Health, 29(1), 89-98.
Mikalsen S-O, Holen I & Sanner T (1990) Morphological transformation and catalase activity of syrian hamster embryo cells treated with hepatic peroxisome proliferators, TPA and nickel sulphate. Cell Biology and Toxicology, 6(1), 1-13.
Llorente A, Blasco MT, Espuny I, Guiu M, Ballaré C, Blanco E, Caballé A, Bellmunt A, Salvador F, Morales A , Nuñez M et al () MAF amplification licenses ERα through epigenetic remodelling to drive breast cancer metastasis. Nature Cell Biology.
Thorne JL, Holen I & Corfe BM () 2^nd Nutrition and Cancer Networking Meeting Nutrition and Breast Cancer: Translating Evidence into Practice. Proceedings of the Nutrition Society, 1-8.
Hughes R, Chen X, Cowley N, Ottewell PD, Hawkins RJ, Hunter KD, Hobbs JK, Brown NJ & Holen I () Osteoblast-Derived Paracrine and Juxtacrine Signals Protect Disseminated Breast Cancer Cells from Stress. Cancers, 13(6), 1366-1366.
Bradbury S, Rennicks S, Evans A, del CBM, Holen I & Ottewell P () Blocking IL-1R signalling inhibits breast cancer growth and bone metastases by altering the tumour microenvironment. Bone Abstracts.
Haider M-T, Ottewell PD, Brown NJ, Lefley DV & Holen I () Peripheral tumour re-growth following combination therapy - role of the bone microenvironment. Bone Abstracts.
Chen X, Hughes R, Mullin N, Hawkins RJ, Holen I, Brown NJ & Hobbs JK () Mechanical Heterogeneity in the Bone Microenvironment as Characterised by Atomic Force Microscopy. View this article in WRRO
Ran R, Harrison H, Ariffin NS, Ayub R, Pegg HJ, Deng W, Mastro A, Ottewell PD, Fowles AM, Blyth SMMK , Holen I et al () RUNX/CBFβ transcription factor complexes promote the phenotypic plasticity of metastatic breast cancer cells.
Wilson C, Nutter F, Brown H, Coleman R & Holen I () Effects of the female hormone inhibin-A in vivo: potential contribution to the antitumour effect of Zoledronic acid. Bone Abstracts.
Quayle LA, Spicer A, Ottewell PD & Holen I () Transcriptomic Profiling Reveals Novel Candidate Genes and Signalling Programs in Breast Cancer Quiescence and Dormancy. Cancers, 13(16), 3922-3922.

Chapters

Holen I, Saleh L, Ottewell PD & Lawson MA (2022) In vivo models used in studies of bone metastases, Bone Cancer (pp. 35-53). Elsevier
Coleman RE, Brown J & Holen I (2020) Bone Metastases, Abeloff's Clinical Oncology (pp. 809-830.e3). Elsevier
Coleman RE, Croucher PI, Padhani AR, Clézardin P, Chow E, Fallon M, Guise T, Colangeli S, Capanna R & Costa L (2020) Bone metastases
Holen I & Lawson MA (2015) In vivo models used in studies of bone metastases, Bone Cancer (pp. 503-518). Elsevier
Alix-Panabieres C, Arlt MJE, Bataille R, Bedard G, Berthold DR, Bianco P, Blanchard F, Blay J-Y, Bolton D, Bolzoni M , Born W et al (2015) List of Contributors, Bone Cancer (pp. xi-xv). Elsevier
Holen I & Lawson MA (2015) In vivo models used in studies of bone metastases, Bone Cancer: Primary Bone Cancers and Bone Metastases: Second Edition (pp. 503-518).
Coleman RE & Holen I (2014) Bone Metastases, Abeloff's Clinical Oncology (pp. 739-763.e3). Elsevier
Coleman RE & Holen I (2013) Bone Metastases, Abeloff's Clinical Oncology: Fifth Edition (pp. 739-763).
Holen I & Lawson MA (2010) In vivo Models Used in Studies of Bone Metastases, Bone Cancer (pp. 347-363). Elsevier
Ando K, Arslandemir C, Bell WC, Berdal A, Berthold D, Bhat BM, Bhat RA, Bhattacharyya S, Billiard J, Blanchard F , Bodine PVN et al (2010) List of Contributors, Bone Cancer (pp. xi-xv). Elsevier
Holen I & Lawson MA (2010) In vivo models used in studies of bone metastases, Bone Cancer (pp. 347-363).
Abbruzzese JL, Abeloff MD, Abou-Alfa GK, Abrahm JL, Abrams JS, Acs G, Aisner J, Aisner SC, Alani RM, Alberts SR , Ambinder RF et al (2008) Contributors, Abeloff's Clinical Oncology (pp. xi-xxvi). Elsevier
Coleman RE & Holen I (2008) Bone Metastases, Abeloff's Clinical Oncology (pp. 845-871). Elsevier
Croucher PI, Holen I & Hargreaves PG (2000) Inhibiting cytokine-processing enzymes, Novel Cytokine Inhibitors (pp. 103-122). Birkhäuser Basel
Seglen PO, Holen I & Gordon PB (1993) Role of Calcium, Protein Phosphorylation and the Cytoskeleton in Hepatocytic Autophagy, Molecular Mechanisms of Membrane Traffic (pp. 339-349). Springer Berlin Heidelberg
Seglen PO, Gordon PB, Holen I, Høyvik H, Kovács AL, Strømhaug PE & Berg TO (1992) Autophagic-Endocytic Interactions in Hepatocytes, Endocytosis (pp. 247-254). Springer Berlin Heidelberg

Conference proceedings papers

Baron-Hay S, Theodoulou E, Porter I, Wilson C, Holen I, Harper-Wynne C & Brown J (2020) Abstract P2-18-08: Inclusion of adjuvant bone-modifying agents for early breast cancer into standard clinical practice: Challenges and lessons learnt from an international collaboration. Poster Session Abstracts
Saleh L, Ottewell PD, Brown JE, Wood SL, Brown NJ, Wilson C, Park C & Holen I (2020) Preventing the progression of breast cancer bone metastasis by CDK inhibition. BREAST CANCER RESEARCH AND TREATMENT, Vol. 180(2) (pp 537-538)
Holen I (2020) Highlights of the last year: basic research. BREAST CANCER RESEARCH AND TREATMENT, Vol. 180(2) (pp 587-587)
Chen X, Hughes R, Mullin N, Hawkins R, Holen I, Brown N & Hobbs J (2019) Supracellular Mechanical Architecture of the Intact Bone Microenvironment. EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS, Vol. 48 (pp S100-S100)
Ottewell PD, Lefley DV, Freeman K, Gregory WM, Hanby AM, Spicer-Hadlington AR, Liu X, Bradbury SM, Hambley L, Allocca G , Cookson V et al (2019) Abstract P1-05-01: Breast cancer cell-derived IL-1B drives metastasis and colonisation of the bone microenvironment. Poster Session Abstracts
Hughes R, Ottewell P, Hobbs J, Holen I & Brown NJ (2019) Breast Cancer Metastasis to Bone: The Role of the Perivascular Niche in Regulating Tumour Cell Dormancy. JOURNAL OF VASCULAR RESEARCH, Vol. 56 (pp 17-18)
Ubellacker JM, Baryawno N, Severe N, DeCristo MJ, Sceneay J, Haider M-T, Rhee CS, Qin Y, Holen I, Gregory WM , Brown JE et al (2018) Abstract B13: Plasma G-CSF levels are predictive of lack of response to zoledronic acid treatment in reducing breast cancer recurrence. Early Clinical Opportunities
(2018) 1st UK Interdisciplinary Breast Cancer Symposium—15th–16th January 2018. Breast Cancer Research and Treatment, Vol. 167(1) (pp 309-405)
Lefley D, Nutter F, Brown H, Tulotta C, Eyre R, Clarke R, Alferez D, Wilkinson M, Holen I & Ottewell P (2017) Human specific models for studying ER plus ve and ER- ve breast cancer bone metastasis. CLINICAL & EXPERIMENTAL METASTASIS, Vol. 34(8) (pp 516-516) View this article in WRRO
Haider MT, Holen I, Brown NJ & Hunter K (2015) SHORT-TERM IN VIVO ADMINISTRATION OF CABOZANTINIB INDUCES RAPID MODIFICATION OF THE BONE MARROW VASCULARITY. JOURNAL OF VASCULAR RESEARCH, Vol. 52 (pp 28-28)
Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Marshall H, Banks RE, Selby PJ, Coleman RE & Brown JE (2013) Abstract P2-11-07: Proteins predictive of bone metastasis development in breast cancer patients. Poster Session Abstracts
Byrne M, Ottewell PD, Holen I, Sanderson T & Cross SS (2012) The Use of p63 in Distinguishing In Situ and Invasive Tumour in the PyMT Mouse Model of Breast Cancer. JOURNAL OF PATHOLOGY, Vol. 228 (pp S38-S38)
Kobayashi-Sakamoto M, Isogai E, Hirose K, Okumura K, Holen I & Chiba I (2011) THROMBIN INDUCES OSTEOPROTEGERIN PRODUCTION VIA PHOSPHATIDYLINOSITOL 3-KINASE PATHWAY IN HUMAN MICROVASCULAR ENDOTHELIAL CELLS. INFLAMMATION RESEARCH, Vol. 60 (pp 216-217)
Brown HK, Ottewell PD, Evans CA, Coleman RE & Holen I (2011) Early intervention with a single dose of doxorubicin followed by zoledronic acid induces sustained inhibition of breast cancer-induced bone disease in a mouse model. BONE, Vol. 48 (pp S255-S255)
Ottewell PD, Whitworth J & Holen I (2011) THE ROLE OF PLAKOGLOBIN IN THE INITIATION OF BREAST CANCER METASTASES. ANNALS OF ONCOLOGY, Vol. 22 (pp 32-32)
Brown JE, Cameron D, Coleman R, Fallowfield L, Holen I, Jones AL & Thompson A (2011) UK INNOVATORS IN BREAST CANCER: AN INITIATIVE TO SUPPORT THE NEXT GENERATION OF BREAST CANCER RESEARCHERS (ON BEHALF OF PAST AND PRESENT 'UK INNOVATORS'). ANNALS OF ONCOLOGY, Vol. 22 (pp 58-58)
Ottewell PD, Brown H, Rogers TL, Lefley DV, Evans AC, Wind N, Cross SS, Brown N, Coleman R & Holen I (2011) PREVENTION OF SPONTANEOUS MAMMARY TUMOUR GROWTH BY SEQUENTIAL ADMINISTRATION OF DOXORUBICIN AND ZOLEDRONIC ACID IN AN IMMUNOCOMPETENT MOUSE MODEL. ANNALS OF ONCOLOGY, Vol. 22 (pp 29-29)
Lunj S, Staton CA, Holen I, Ballmer-Hofer K, Reed MW & Brown NJ (2011) Abstract 5131: Escape from breast cancer therapy, are neuropilins the key. Tumor Biology
Ottewell PD, Brown H, Evans CA, Wind NS, Brown NJ, Coleman RE & Holen I (2011) First evidence for anti-tumour effects of doxorubicin and zoledronic acid from an immunocompetent mouse model. BONE, Vol. 48(1) (pp S42-S42)
Wind NS, Brown H, Ottewell PD, Sadej R, Romanska H, Berditchevski F & Holen I (2011) Does differential expression of CD151 affect the ability of beast cancer cells to establish tumours in bone?. BONE, Vol. 48(1) (pp S45-S45)
Brown* HK, Ottewell PD, Evans CA, Coleman RE & Holen I (2011) Combination vs single agent treatment: The effects of zoledronic acid+/−doxorubicin on breast tumour growth in bone prior to development of osteolytic bone disease. Bone, Vol. 48(1) (pp S41-S41)
Westbrook JA, Peng J, Cairns DA, Ottewell PD, Holen I, Coleman RE, Selby PJ, Banks RE & Brown JE (2011) Towards biomarkers of bone-metastasis using cellular proteomics. BONE, Vol. 48(1) (pp S33-S33)
Brown HK, Ottewell PD, Evans CA & Holen I (2011) Changes in osteoblast and osteoclast number rely on direct contact with breast cancer cells - Evidence from a longitudinal study of bone metastasis. BONE, Vol. 48(1) (pp S40-S41)
Winter MC, Evans A, Holen I & Coleman RE (2011) The addition of zoledronic acid to combination chemotherapy decreases circulating serum levels of vascular endothelial growth factor (VEGF) in early breast cancer. BONE, Vol. 48(1) (pp S30-S31)
Winter MC, Syddall SP, Cross SS, Evans A, Ingram CE, Jolley IJ, Hatton MQ, Mori S, Holen I & Coleman RE (2010) Abstract P1-11-01: ANZAC: A Randomised Neoadjuvant Biomarker Study Investigating the Anti-Tumour Activity of the Addition of Zoledronic Acid to Chemotherapy in Breast Cancer. Poster Session Abstracts
Holen I, Ottewell PD & Coleman RE (2010) Abstract P6-14-03: Zoledronic Acid Reduces Breast Tumour Growth When Combined with Chemotherapy — Emerging Evidence of Anti-Tumour Effects Outside Bone. Poster Session Abstracts
Ottewell PD, Lefely DV, Cross SS, Coleman RE & Holen I (2010) Sustained inhibition of tumour growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid. BONE, Vol. 47 (pp S317-S317)
Brown HK, Ottewell PD, Lefely DV, Coleman RE & Holen I (2010) Effects of doxorubicin followed by zoledronic acid on early, medium and late stage breast tumour growth in bone. BONE, Vol. 47 (pp S318-S319)
Winter MC, Evans A, Holen I & Coleman RE (2010) Exploring the anti-angiogenic potential of zoledronic acid in combination with neoadjuvant chemotherapy in invasive breast cancer. BONE, Vol. 47 (pp S310-S310)
Woodward J, Holen I, Lefley D, Ottewell P & Buttle D (2010) Breast cancer-bone marrow stromal cell interactions modify expression of proteolytic enzymes and regulators of bone turnover. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Vol. 91(2) (pp A45-A46)
Bundred NJ, Landberg G, Coleman RE, Morris J, Winter MC, Holen I, Cramer A, Renshaw L, Grassby S & Dixon JM (2009) Short-term biological effects of zoledronic acid combined with letrozole in postmenopausal women with estrogen receptor-positive invasive breast cancer. JOURNAL OF CLINICAL ONCOLOGY, Vol. 27(15)
Winter MC, Cross SS, Ingram CE, Jolley IJ, Holen I, Hatton MQ, Horsman JM & Coleman R (2009) ANZAC: A NEOADJUVANT BIOMARKER STUDY EXPLORING THE ANTI-TUMOUR ACTIVITY OF THE ADDITION OF ZOLEDRONIC ACID TO CHEMOTHERAPY IN BREAST CANCER. ANNALS OF ONCOLOGY, Vol. 20 (pp 55-55)
Ottewell PD, Leftey DV, Coleman RE & Holen I (2009) Evaluation of the molecular mechanisms for the sequence-dependent, synergistic anti-tumour effects of doxorubicin and zoledronic acid in breast cancer.. CANCER RESEARCH, Vol. 69(2) (pp 200S-201S)
Offewell P, Coleman RE & Holen I (2008) Mechanisms of apoptosis and cell cycle arrest in sub-cutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid. EJC SUPPLEMENTS, Vol. 6(9) (pp 18-18)
Lefley DV, Holen I, Coleman RE & Ottewell PD (2008) Pretreatment of breast cancer cells with doxorubicin facilitates the subsequent uptake of zoledronic acid. BREAST CANCER RESEARCH, Vol. 10 (pp S40-S40) View this article in WRRO
Ottewell PD, Lefley DV, Coleman RE & Holen I (2008) Mechanisms of apoptosis and cell-cycle arrest in subcutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid. BREAST CANCER RESEARCH, Vol. 10 (pp S40-S41) View this article in WRRO
Ottewett P, Coleman R & Holen I (2008) Mechanisms of apoptosis and cell cycle arrest in intra-tibial breast tumours treated sequentially with doxorubicin followed by zoledronic acid. CANCER TREATMENT REVIEWS, Vol. 34 (pp S62-S62)
Ottewett P, Croucher P & Holen I (2008) Breast cancer cells cause a reduction in osteoblast number - An early event in the development of osteolytic bone lesions. CANCER TREATMENT REVIEWS, Vol. 34 (pp S56-S56)
Brown HK & Holen I (2008) Zoledronic acid modulates chromosome separation in breast cancer cells by inhibition of Cenp-F prenylation. CANCER TREATMENT REVIEWS, Vol. 34 (pp S60-S61)
Woodward J, Lefley D, Cross N, Ottewell PD, Buttle DJ, Coleman RE & Holen I (2007) Tumour cell-bone marrow stromal cell interactions modify expression of cathepsin K, ADAMTS-15, TIMP-3 and osteoprotegerin (OPG). INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Vol. 88(6) (pp A97-A97)
Ottewell PD, Deux B, Monkkonen H, Cross SS, Coleman RE, Clezardin P & Holen I (2007) Differential effects of doxorubicin and zoledronic acid on intra-osseous vs extra-osseous breast tumour growth in vivo.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 106 (pp S39-S39)
Ottewell PD, Deux B, Monkkonen H, Coleman RE, Clezardin P & Holen I (2007) Differential effect of doxorubicin and zoledronic acid on intra-osseous vs extra osseous breast tumour growth in vivo. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22(7) (pp 1111-1111)
Woodward JKL, Lefley DV, Cross NA, Ottewell PD, Battle DJ, Coleman RE & Holen I (2007) Tumour cell-bone marrow stromal cell interactions modify expression of cathepsin K, ADAMTS-15, TIMP-3 and osteoprotegerin (OPG). JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22(7) (pp 1142-1143)
Van Pozanki C, Otterwell P, Cross S, Hudis C, Coleman RE & Holen I (2007) Osteoprotegerin (OPG) expression in breast tumors and bone metastases. INT J BIOL MARKER, Vol. 22(1) (pp 83-84)
Kuokkanen J, Monkkonen H, Evans A, Holen I, Jauhiainen M, Auriola S & Monkkonen J (2006) The bisphosphonate treatment related ATP analog formation in different cancer cell lines. BONE, Vol. 39(5) (pp S32-S32)
Ottewell PD, Jones M, Coleman RE & Holen I (2006) Synergistic effects of zoledronic acid and doxorubicin in breast cancer models in vivo. CANCER TREATMENT REVIEWS, Vol. 32 (pp S30-S30)
Holen I, Hannon RA, Ellis SP, Coleman RE & Brown JE (2006) Effects of clodronate on serum osteoprotogerin (OPG) in patients with metastatic bone disease. CANCER TREATMENT REVIEWS, Vol. 32 (pp S40-S40)
Holen I, Santini D, Vincenzi B, Tonini G & Hannon RA (2006) Rapid increase in levels of circulating osteoprotegerin (OPG) in patients with tumour-induced bone disease following zoledronic acid administration. BONE, Vol. 38(3) (pp S75-S75)
Michailidou M, Neville-Webbe HL, Evans CA, Brown NJ, Coleman RE & Holen I (2006) Effects of Zoledronic acid and Paclitaxel on endothelial cells in vitro. BONE, Vol. 38(3) (pp S57-S58)
Monkkonen H, Holen I, Evans A, Jauhiainen M, Auriola S & Monkkonen J (2006) Zoledronic acid induced IPP/ApppI accumulation in different cancer cell lines. BONE, Vol. 38(3) (pp S58-S58)
Neville-Webbe HL, Lefley D, Coleman RE & Holen I (2006) Zoledronic acid (ZOL) and letrozole (LET) induce synergistic levels of apoptosis in breast cancer cells. BONE, Vol. 38(3) (pp S58-S59)
Van Poznak C, Ottewell P, Cross S, Hudis C, Coleman RE & Holen I (2006) Osteoprotegerin (OPG) expression in breast tumours and bone metastases. BONE, Vol. 38(3) (pp S31-S32)
Holen I, Patel R, Lefley DV, Webbe HLN, Coleman RE & Woodward JKL (2006) Effects of zoledronic acid on apoptosis in tumour cell lines; repeated low dosing compared to continuous treatment. BONE, Vol. 38(3) (pp S51-S52)
Kuokkanen J, Monkkonen H, Holen I, Evans CA, Kotilainen HK, Auriola S & Monkkonen J (2006) IPP/ApppI production and cellular drug uptake in synergistic action of doxorubicin and zoledronic acid. BONE, Vol. 38(3) (pp S54-S54)
Cross SS, Ottewell P, Swinscoe M, Majeed AW & Holen I (2006) Osteoprotegerin is strongly expressed in the intratumoural endothelial cells of gastrointestinal carcinomas. JOURNAL OF PATHOLOGY, Vol. 208 (pp 9A-9A)
Holen I, Neville-Webbe H & Coleman RE (2006) Benefits of combined treatments using antiresorptive agents and cytotoxic drugs. BREAST CANCER RESEARCH, Vol. 8 (pp S4-S4) View this article in WRRO
Ottewell PD, Jones M, Coleman RE & Holen I (2006) Synergistic effects of cytotoxic drugs and antiresorptive agents in vitro and in vivo. BREAST CANCER RESEARCH, Vol. 8 (pp S17-S17) View this article in WRRO
Michailidou M, Brown N, Coleman RE & Holen I (2006) Effects of combined treatment with Zometa and Taxol on endothelial cells in vitro. BREAST CANCER RESEARCH, Vol. 8 (pp S18-S18) View this article in WRRO
Ottewell PD, Jones M, Coleman RE & Holen I (2006) Synergistic effects of cytotoxic drugs and anti-resorptive agents in vitro and in vivo.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 100 (pp S290-S290)
Cross SS, Balasubramanian SP, Lippitt JM, Evans CA, Reed MWR & Holen I (2005) Tumour necrosis factor-related apoptosis inducing ligand (TRAIL) is expressed in human breast cancers and has a significant negative association with tumours with poor prognosis.. JOURNAL OF PATHOLOGY, Vol. 207 (pp 27-27)
Cross SS, Balasubramanian SP, Lippitt JM, Evans CA, Reed MWR & Holen I (2005) There is a general loss of expression of receptor activator of nFkB ligand (RANKL) in human breast cancers but retention of expression has a significant negative association with expression of oestrogen receptor (ER). JOURNAL OF PATHOLOGY, Vol. 207 (pp 27-27)
Woodward JKL, Neville-Webbe H, Coleman RE & Holen I (2005) The effects of zoledronic acid and doxorubicin in combination on breast cancer cell invasion in vitro. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20(7) (pp 1299-1299)
Cross SS, Yang Z, Woodward JKL, Balasubramanian SP, Reed MWR, Coleman RE, Brown NJ & Holen I (2005) Tumour endothelial cells express osteoprotegerin (OPG) - A potential role in tumour angiogenesis?. CANCER TREATMENT REVIEWS, Vol. 31 (pp S37-S38)
Neville-Webbe HL, Coleman RE & Holen I (2005) Understanding drug-sequence-dependent synergistic induction of apoptosis by zoledronic acid (ZOL) and doxorubicin (DOX) in breast cancer. CANCER TREATMENT REVIEWS, Vol. 31 (pp S41-S41)
Woodward J, Coleman R, Neville-Webbe H & Holen I (2005) The combined effects of zoledronic acid (ZOL) and doxorubicin (DOX) on breast cancer cell invasion in vitro. CANCER TREATMENT REVIEWS, Vol. 31 (pp S43-S43)
Neville-Webbe HL, Coleman RE & Holen I (2005) Understanding drug-sequence-dependent synergistic induction of apoptosis by zoledronic acid (ZOL) and doxorubicin (DOX) in breast cancer. CANCER TREATMENT REVIEWS, Vol. 31 (pp S28-S28)
Evans CA, Neville-Webbe HL, Coleman RE & Holen I (2005) Differential induction of apoptosis following sequential treatments using cytotoxic drugs and zoledronic acid. CANCER TREATMENT REVIEWS, Vol. 31 (pp S36-S36)
Croucher P, Holen I & Eaton C (2005) Nonosseous effects of osteoprotegerin. CANCER TREATMENT REVIEWS, Vol. 31 (pp S14-S15)
Spencer A, Cross SS, Holen I, Ackroyd R, Stoddard CJ & Bury JP (2004) Expression of osteoprotegerin (OPG) and TRAIL in oesophageal carcinoma and non-neoplastic gastric and oesophageal mucosa. JOURNAL OF PATHOLOGY, Vol. 204 (pp 50A-50A)
Neville-Webbe HL, Evans CA, Coleman RE & Holen I (2004) Zoledronic acid (ZOL) in combination with doxorubicin (DOX) has synergistic effects on apoptosis of breast cancer cells (BCCs) in vitro. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1598-1598)
Cross SS, Balasubramanian SP, Evans CA, Reed MWR & Holen I (2004) Osteoprotegerin is overexpressed in breast cancers and intratumoural endothelial cells and is significantly associated with tumour grade but not with axillary lymph node metastasis. JOURNAL OF PATHOLOGY, Vol. 204 (pp 14A-14A)
Nyambo R, Neville-Webbe H, Holen I, Cross NA, Hamdy FC & Eaton CL (2004) Human bone marrow stromal cells protect prostate and breast cancer cells from TRAIL-induced apoptosis. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1572-1572)
Eaton CL, Wells JM, Holen I, Croucher PI & Hamdy FC (2004) Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1585-1585)
Neville-Webbe HL, Evans CA, Coleman RE & Holen I (2004) Combined treatments of breast cancer cells using bisphosphonates and doxorubicin. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(6) (pp 1035-1035)
Neville-Webbe H, Coleman RE & Holen I (2004) Zoledronic acid and paclitaxel have synergistic antitumor activity and induce apoptotic tumor cell death at clinically relevant concentrations. BREAST CANCER RESEARCH AND TREATMENT, Vol. 88 (pp S132-S132)
Neville-Webbe HL, Evans A, Coleman RE & Holen I (2004) Sequential exposure of breast cancer cells to cytotoxic agents and zoledronic acid induces synergistic increase in apoptotic cell death.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 88 (pp S72-S72)
Neville-Webbe HL, Evans A, Coleman RE & Holen I (2004) Presence of BRCA1 gene enhances levels of apoptosis induced by combination treatment with doxorubicin (DOX) and zoledronic acid (ZOL).. BREAST CANCER RESEARCH AND TREATMENT, Vol. 88 (pp S73-S73)
Van Poznac C, Cross SS, Saggese M, Lippitt JM, Hudis C, Coleman RE & Holen I (2004) Human breast cancers express osteoprotegerin (OPG), tumor necrosis factor-related apoptosis inducing ligand (TRAIL) and receptor activator of nFkB ligand (RANKL). BONE, Vol. 34 (pp S29-S29)
Evans A, Neville-Webbe H, Coleman RE & Holen I (2004) Zoledronic acid and TRAIL induce synergistic increase in apoptotic tumor cell death. BONE, Vol. 34 (pp S56-S56)
Neville-Webbe H, Coleman RE & Holen I (2004) Paclitaxel and zoledronic acid induce synergistic increase in apoptotic tumour cell death at clinically relevant concentrations. BONE, Vol. 34 (pp S67-S68)
Cross SS, Van Poznak C, Hudis C & Holen I (2003) The expression of osteoprotegerin co-localises with columnar cell change in human breast tissue. JOURNAL OF PATHOLOGY, Vol. 201 (pp 32A-32A)
Van Poznak CH, Cross SS, Hudis C, Panageas KS, Coleman RE & Holen I (2003) Osteoprotegerin expression correlates with ER/PR status in human breast tumors.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 18 (pp S310-S310)
Naylor KE, Rogers A, Smith C, Hall V, Fraser RB, Holen I, Lippitt J, Eastell R & Blumsohn A (2003) Source of maternal serum osteoprotegerin during human pregnancy. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 18(7) (pp 1376-1376)
Neville-Webbe HL, Evans A, Eaton C, Coleman R & Holen I (2003) Bone marrow stromal cell-derived osteoproteger in (OPG) protects breast cancer cells from trail-induced apoptosis. BRITISH JOURNAL OF CANCER, Vol. 88 (pp S25-S25)
Nyambo R, Cross NA, Lippit J, Holen I, Bryden AAG & Eaton CL (2003) Human bone marrow stromal cells (hBMSC) protect prostate cancer cells from trail induced apoptosis. BRITISH JOURNAL OF CANCER, Vol. 88 (pp S26-S26)
Chandrasekharan S, Buttle DJ, Holen I, Cross NA & Hamdy FC (2003) Expression pattern of the ADAMTS (A Disintegrin And Metalloproteinase with ThromboSpondin motifs) proteinases in human prostate cancer celllines. JOURNAL OF UROLOGY, Vol. 169(4) (pp 58-58)
Van Poznak CH, Cross SS, Hudis C, Norton L, Panageas KS, Coleman RE & Holen I (2003) Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis inducing ligand (TRAIL) are expressed in human breast tumors.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 82 (pp S162-S162)
Holen I, Wells JM, Croucher PI, Evans CA, Lippitt JM, Coleman RE, Jagdev SP, Hamdy FC & Eaton CL (2002) The role of osteoprotegerin in breast and prostate cancer. J BONE MINER RES, Vol. 17(7) (pp 1339-1339)
Holen I, Croucher PI, Evans AC, Lippitt JM, Hamdy FC, Coleman RE & Eaton CL (2002) OPG is a survival factor for breast- and prostate cancer cells in vitro. BONE, Vol. 30(3) (pp 28S-28S)
Gordon PB, Holen I & Seglen PO (1991) Effects of adrenergic agonists and antagonists on autophagic activity in isolated rat liver cells. Biomedica Biochimica Acta, Vol. 50(4-6) (pp 383-387)
Holen I, Gordon PB & Seglen PO (1991) Role of cyclic nucleotides in the control of hepatic autophagy. Biomedica Biochimica Acta, Vol. 50(4-6) (pp 389-392)

Website content

Holen I (2015) Meet Our Editorial Board Member:.

Other

Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) Supplementary figure 2 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.
Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) Supplementary figure legends from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.
Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) Supplementary figure 5 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.
Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) Supplementary figure 3 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.
Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) Supplementary table 1 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.
Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) Supplementary figure 1 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.
Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) Supplementary figure 4 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.
Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) Supplementary figure 1 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.
Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) Supplementary figure 4 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.
Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) Data from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.
Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) Supplementary figure 6 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.
Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) Supplementary figure 7 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.
Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) Supplementary figure 5 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.
Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) Supplementary figure 6 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.
Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) Data from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.
Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) Supplementary figure 7 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.
Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) Supplementary figure legends from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.
Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) Supplementary table 1 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.
Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) Supplementary figure 3 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.
Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) Supplementary figure 2 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.

Preprints

Chen X, Hughes R, Mullin N, Hawkins RJ, Holen I, Brown NJ & Hobbs JK () Atomic force microscopy reveals the mechanical properties of breast cancer bone metastases, Cold Spring Harbor Laboratory. View this article in WRRO

Research group

PhD students

Elisavet Theodoulou
Jacky Wong

Professional activities and memberships

I am the Science Lead for the Sheffield Experimental Cancer Medicine Centre as well as a Trustee of Breast Cancer Now, and the NIHR Doctoral Research Fellowship review panel. I am a member of the executive committee that organises the UK Interdisciplinary Breast Cancer Symposium (2018, 2020) that will now be a bi-annual meeting.

I am the incoming Chair of the Executive Committee of British Association for Cancer Research, serve on a number of international expert review panels and committees and journal editorial boards.